Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Equities research analysts at Lifesci Capital dropped their FY2025 earnings per share estimates for Astria Therapeutics in a research report issued on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky now anticipates that the biotechnology company will earn ($1.97) per share for the year, down from their prior forecast of ($1.95). The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01.

A number of other research firms have also recently commented on ATXS. JMP Securities started coverage on Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday. Citizens Jmp upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $26.67.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $6.45 on Friday. The stock has a market cap of $364.00 million, a PE ratio of -3.09 and a beta of 0.69. Astria Therapeutics has a one year low of $5.73 and a one year high of $16.90. The stock has a fifty day moving average of $7.19 and a 200 day moving average of $9.57.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics in the fourth quarter worth about $41,000. Tower Research Capital LLC TRC increased its position in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after buying an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Astria Therapeutics during the fourth quarter worth about $50,000. Virtus ETF Advisers LLC purchased a new stake in shares of Astria Therapeutics during the fourth quarter worth about $65,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Astria Therapeutics during the fourth quarter worth about $91,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.